Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells.
about
The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapyDirect and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney TransplantationAge dependent differences in the kinetics of γδ T cells after influenza vaccination.Capturing needles in haystacks: a comparison of B-cell receptor sequencing methods.Clinical applications of gamma delta T cells with multivalent immunity.Ex vivo expanded human circulating Vδ1 γδT cells exhibit favorable therapeutic potential for colon cancer.Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.γδ T Cell-Mediated Immunity to Cytomegalovirus Infection.New immunotherapeutic strategies for the treatment of neuroblastoma.High-throughput sequencing of the T-cell receptor repertoire: pitfalls and opportunities.Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy.Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model.Immunoengineering with biomaterials for enhanced cancer immunotherapy.Gamma-delta (γδ) T cells: friend or foe in cancer development?Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.Dual Face of Vγ9Vδ2-T Cells in Tumor Immunology: Anti- versus Pro-Tumoral Activities.Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.
P2860
Q26859775-47D8E7C2-DFFA-480E-91E9-B80EBBF71BDAQ26863724-573F3A34-9A7E-4212-A979-4D391D906853Q33898222-2BF6ADAE-EDD6-495A-AA53-26F8BC06FC65Q34570623-C0AC21E0-ED77-4597-951B-52C13E23752DQ34677859-0BBB5473-C71E-48BC-881F-7A87A5C3152DQ35506504-2717F566-BFBB-4531-934F-E0C86430FA66Q36597374-F69ED9DD-4939-474C-93BF-FAFCB9B9E761Q37109545-AADBAFC9-B02D-4E31-8D8A-5A323781481DQ37632938-65B3C3B0-7DC6-4087-A09E-B8765FA98A42Q38389316-7D31D890-FF5B-4C13-81A3-5E7792707FE6Q39026323-32956014-FFF2-4A8C-BD66-797E6E12C84BQ39832849-153EE8EB-9217-4BDB-81BB-BBDD5EABFEE4Q40146526-9D0EFB96-9718-4A89-8B14-A29EB4604414Q47732542-F68407B5-65FE-4D88-A43B-3D310C46300EQ47742552-FC629823-6007-4EBD-94E2-574BCAA953F6Q50025651-1D60761A-76D9-4B27-A8A3-1462462E7E81Q50034000-3F744ED4-7532-441B-ADB4-81F092D5BE4BQ50144881-ABD4B0B9-21AB-46B4-B021-98D55CDD863AQ55311835-C9B13A4F-7C9E-453D-94DF-9B94309F4EB6
P2860
Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Neuroblastoma killing properti ...... cial antigen-presenting cells.
@ast
Neuroblastoma killing properti ...... cial antigen-presenting cells.
@en
type
label
Neuroblastoma killing properti ...... cial antigen-presenting cells.
@ast
Neuroblastoma killing properti ...... cial antigen-presenting cells.
@en
prefLabel
Neuroblastoma killing properti ...... cial antigen-presenting cells.
@ast
Neuroblastoma killing properti ...... cial antigen-presenting cells.
@en
P2093
P2860
P1476
Neuroblastoma killing properti ...... cial antigen-presenting cells.
@en
P2093
Anna Capsomidis
Ayda Abolhassani
Barry Flutter
Jennifer Frosch
Jennifer Heuijerjans
John Anderson
Kenth Gustafsson
Lisa Carter
Mengyong Yan
Mike Hubank
P2860
P304
P356
10.1158/1078-0432.CCR-13-3464
P407
P577
2014-06-03T00:00:00Z